1. Home
  2. ELVN vs EOS Comparison

ELVN vs EOS Comparison

Compare ELVN & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • EOS
  • Stock Information
  • Founded
  • ELVN 2016
  • EOS 2005
  • Country
  • ELVN United States
  • EOS United States
  • Employees
  • ELVN N/A
  • EOS N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • EOS Trusts Except Educational Religious and Charitable
  • Sector
  • ELVN Health Care
  • EOS Finance
  • Exchange
  • ELVN Nasdaq
  • EOS Nasdaq
  • Market Cap
  • ELVN 927.8M
  • EOS 1.2B
  • IPO Year
  • ELVN 2020
  • EOS N/A
  • Fundamental
  • Price
  • ELVN $19.65
  • EOS $24.13
  • Analyst Decision
  • ELVN Strong Buy
  • EOS
  • Analyst Count
  • ELVN 5
  • EOS 0
  • Target Price
  • ELVN $39.60
  • EOS N/A
  • AVG Volume (30 Days)
  • ELVN 715.5K
  • EOS 84.1K
  • Earning Date
  • ELVN 08-12-2025
  • EOS 01-01-0001
  • Dividend Yield
  • ELVN N/A
  • EOS 6.80%
  • EPS Growth
  • ELVN N/A
  • EOS N/A
  • EPS
  • ELVN N/A
  • EOS N/A
  • Revenue
  • ELVN N/A
  • EOS N/A
  • Revenue This Year
  • ELVN N/A
  • EOS N/A
  • Revenue Next Year
  • ELVN N/A
  • EOS N/A
  • P/E Ratio
  • ELVN N/A
  • EOS N/A
  • Revenue Growth
  • ELVN N/A
  • EOS N/A
  • 52 Week Low
  • ELVN $13.30
  • EOS $15.62
  • 52 Week High
  • ELVN $30.03
  • EOS $20.63
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 46.72
  • EOS 72.15
  • Support Level
  • ELVN $20.22
  • EOS $22.84
  • Resistance Level
  • ELVN $21.90
  • EOS $24.29
  • Average True Range (ATR)
  • ELVN 1.55
  • EOS 0.24
  • MACD
  • ELVN -0.24
  • EOS 0.05
  • Stochastic Oscillator
  • ELVN 20.07
  • EOS 91.03

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About EOS Eaton Vance Enhance Equity Income Fund II

Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.

Share on Social Networks: